When co-administering CYP2D6 inhibitors with other therapies to treat malaria or other inflammatory diseases, evaluating potential DDIs is essential, as they may affect the metabolism of CYP2D6 substrates (Rendic and Guengerich 2020). This evidence concerns the gene CYP2D6 and malaria.